KBA-1636

N/A

Report date: 2023/12/22 11:24:10

Base Information

Drug NameKBA-1636

Drug Alias NameAT 1636-bispecifc antibodyKBA-1636KBA1636CD3-AT 1636AT 1636 IYN

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Cadherin-1

TargetsCadherin-1

Therapy Area/IndicationsColonic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAimm Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesKling Biotherapeutics BV

Inactive CompaniesN/A

Active IndicationsColonic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A